Table 4 Baseline and follow-up levels of total cholesterol and LDL cholesterol in HLP patients with different MDR1 genotypes who underwent Rosuvastatin, Atorvastatin and Simvastatin therapy (Subgroups BI, BII, BIII)

7.08 ± 0.14

4.59 ± 0.17*

−35.1%

5.10 ± 0.17

3.31 ± 0.19*

−35.1%

7.15 ± 0.17

4.70 ± 0.16*

−34.3%

5.05 ± 0.18

3.11 ± 0.21*

−38.4%

7.16 ± 0.16

4.88 ± 0.15*

−31.8%

4.92 ± 0.19

2.96 ± 0.20*

−38.8%

7.14 ± 0.13

4.76 ± 0.14*

−33.3%

5.00 ± 0.15

3.09 ± 0.17*

−38.2%

7.13 ± 0.18

5.02 ± 0.22*

−29.6%

4.92 ± 0.19

3.29 ± 0.21*

−33.1%

7.14 ± 0.17

5.15 ± 0.24*

−27.9%

5.03 ± 0.18

3.35 ± 0.20*

−33.4%

7.17 ± 0.16

5.14 ± 0.25*

−28.3%

4.98 ± 0.21

2.98 ± 0.22*

−30.1%

7.15 ± 0.15

5.11 ± 0.23*

−28.5%

4.97 ± 0.17

3.16 ± 0.19*

−36.4%

7.16 ± 0.23

5.14 ± 0.31*

−28.9%

5.14 ± 0.20

3.33 ± 0.23*

−35.1%

7.21 ± 0.21

5.07 ± 0.32*

−29.7%

5.07 ± 0.19

3.10 ± 0.25*

−38.9%

7.17 ± 0.17

5.01 ± 0.28*

−30.1%

5.13 ± 0.18

3.12 ± 0.24*

−39.1%

7.18 ± 0.19

5.05 ± 0.29*

−29.6%

5.11 ± 0.16

3.16 ± 0.21*

−38.1%